2021-01-03,b'$AXSM Lets see how this turns out -2.15 % https://t.co/wOUHm71Yjc'
2021-01-03,b'RT @semodough: LR - neuro comments $ACAD Nuplazid: PDP is $500M-$1B but adding DRP&amp;schizophrenia negative symptoms can take this drug to ~$\xe2\x80\xa6'
2021-01-03,b'RT @semodough: LR - neuro comments $ACAD Nuplazid: PDP is $500M-$1B but adding DRP&amp;schizophrenia negative symptoms can take this drug to ~$\xe2\x80\xa6'
2021-01-03,b'RT @semodough: LR - neuro comments $ACAD Nuplazid: PDP is $500M-$1B but adding DRP&amp;schizophrenia negative symptoms can take this drug to ~$\xe2\x80\xa6'
2021-01-03,b'RT @semodough: LR - neuro comments $ACAD Nuplazid: PDP is $500M-$1B but adding DRP&amp;schizophrenia negative symptoms can take this drug to ~$\xe2\x80\xa6'
2021-01-03,"b'LR - neuro comments $ACAD Nuplazid: PDP is $500M-$1B but adding DRP&amp;schizophrenia negative symptoms can take this drug to ~$4B\n$ITCI Caplyta: Schizophrenia is $250-500M, but bipolar depression~$1B&amp;adjunctive MDD to ~$2B $AXSM AXS-05 MDD is $500M-$1B,AAD could drive drug to ~$2B\xf0\x9f\x91\x8d'"
2021-01-03,b'$AXSM This one is getting bipolar : ) -2.15 % change recently https://t.co/wOUHm71Yjc'
2021-01-03,b'$ICNB to communicate exciting new JV to shareholders within the next 2 weeks\nhttps://t.co/fK8PPZ6hwp\n\n$TGLO $TGH $TGA $TFX $TFSL $TEP $TSCRF $AXU $AXSM $AXDX $AWR $AWI $AWF $AWAW $AVXL'
2021-01-02,"b'RT @JD4for4: My top names for 2021 \xe2\x80\x94 $XAIR - FDA approval PPHN &amp; NTM data (5x upside), $TRIL ASH data + solid tumors (3x), $IPOC AI health\xe2\x80\xa6'"
2021-01-02,b'$AXSM in Downtrend: RSI indicator exits overbought zone. View odds for this and other indicators: https://t.co/1tq1K0grqT #AxsomeTherapeutics #stockmarket #stock #technicalanalysis #money #trading #investing #daytrading #news #today https://t.co/Npy46txcPQ'
2021-01-02,b'@MoneyTrails9 @TonyorAnthony69 @sunrgu @Jessecdghi Im long $KALA  too.  But i compare it with $AVDL.  RA was invested in with good size. But no BO there and $AXSM with a better product in narcolepsy.  And RA is no more invested in $AVDL.'
2021-01-02,"b""RT @pawcio2009: If you haven't yet submitted your #biopick2021, please do so today as today is the deadline. Over 700 entries so far, that'\xe2\x80\xa6"""
2021-01-02,b'$AXSM $89.62+ by soon?.. -2.15 % change recently https://t.co/KMYVaiFakO'
2021-01-02,"b""RT @pawcio2009: If you haven't yet submitted your #biopick2021, please do so today as today is the deadline. Over 700 entries so far, that'\xe2\x80\xa6"""
2021-01-02,"b""RT @pawcio2009: If you haven't yet submitted your #biopick2021, please do so today as today is the deadline. Over 700 entries so far, that'\xe2\x80\xa6"""
2021-01-02,"b""RT @pawcio2009: If you haven't yet submitted your #biopick2021, please do so today as today is the deadline. Over 700 entries so far, that'\xe2\x80\xa6"""
2021-01-02,b'RT @intratio: https://t.co/uXrnzGx5C2 Axsome Therapeutics Inc The artificial intelligence assessed this company s stock price is aligned wi\xe2\x80\xa6'
2021-01-02,"b""If you haven't yet submitted your #biopick2021, please do so today as today is the deadline. Over 700 entries so far, that's incredible \xf0\x9f\x99\x8f. Let's find next $tril or better yet $axsm \xf0\x9f\x98\x89\xf0\x9f\x92\xaa"""
2021-01-02,"b'RT @_B_I_O_T_E_C_H_: $AXSM AXSOME THERAPEUTICS INC - STUDY ACHIEVED DURABLE RELIEF, WITH APPROXIMATELY 85% OF PATIENTS FREE FROM RESCUE MED\xe2\x80\xa6'"
2021-01-02,"b'RT @_B_I_O_T_E_C_H_: $AXSM AXSOME THERAPEUTICS INC - STUDY ACHIEVED DURABLE RELIEF, WITH APPROXIMATELY 85% OF PATIENTS FREE FROM RESCUE MED\xe2\x80\xa6'"
2021-01-02,b'$AXSM Always buy on Fear ..\xef\xbf\xbd\xef\xbf\xbd\xef\xbf\xbd\xef\xbf\xbd\xef\xbf\xbd\xef\xbf\xbd\xef\xbf\xbd\xef\xbf\xbd\xef\xbf\xbd\xef\xbf\xbd\xef\xbf\xbd\xef\xbf\xbd\xef\xbf\xbd\xef\xbf\xbd -2.15 % change recently https://t.co/wOUHm71Yjc'
2021-01-01,b'$AXSM in Downtrend: RSI indicator exits overbought zone. View odds for this and other indicators: https://t.co/2Aq9Lg6m3H #AxsomeTherapeutics #stockmarket #stock #technicalanalysis #money #trading #investing #daytrading #news #today https://t.co/3YcMYuYwFR'
2021-01-01,b'$AXSM what a Company  -2.07 % change recently https://t.co/KMYVaiFakO'
2021-01-01,b'$AXSM Mid-cap biotech with some worth watching catalysts as highlighted by @semodough. Chart is in a healthy short term uptrend with momentum.\n\nInsiders also loaded on a significant amount of employee stock options and RSUs earlier in December. Putting this on watch. https://t.co/OcAQmYwD6r https://t.co/e9Yk3LovIO'
2021-01-01,"b'RT @semodough: $AXSM 2 catalysts JAN 2021 AXS-07: With successful completion of long-term MOVEMENT study,AXS-07 NDA is on track for submiss\xe2\x80\xa6'"
2021-01-01,b'RT @LifeSciFocus: $AXSM COWEN CONTINUES TO VIEW SHARES AS UNDERVALUED\n\nPRICE TARGET: $135 https://t.co/niqoXNM1Q6'
2021-01-01,"b'RT @semodough: $AXSM 2 catalysts JAN 2021 AXS-07: With successful completion of long-term MOVEMENT study,AXS-07 NDA is on track for submiss\xe2\x80\xa6'"
2021-01-01,"b'RT @semodough: $AXSM 2 catalysts JAN 2021 AXS-07: With successful completion of long-term MOVEMENT study,AXS-07 NDA is on track for submiss\xe2\x80\xa6'"
2021-01-01,"b'$AXSM 2 catalysts JAN 2021 AXS-07: With successful completion of long-term MOVEMENT study,AXS-07 NDA is on track for submission in 1Q 2021.\nAXS-05 in depression: January 2021 MDD NDA filing; COMET Phase 3 long-term safety study completed; 1H21 Readout from MERIT Phase 2 study. https://t.co/wlBE7U9Ab1'"
2021-01-01,b'Recent $AXSM technical alerts: MACD Bearish Signal Line Cross plus 6 more alerts... https://t.co/GD05wWU2WA'
2021-01-01,b'RT @newsfilterio: New patent application published for: Pharmaceutical Compositions Comprising Meloxicam $AXSM https://t.co/0I47d23kal'
2021-01-01,"b'AUXOLI has been filed for trademark by Axsome Therapeutics, Inc. https://t.co/Cruph069vk #AUXOLI $AXSM https://t.co/rRGu3hrn8J'"
2021-01-01,b'RT @MarcJacksonLA: $AXSM Axsome\xe2\x80\x99s Migraine Drug Provides Relief in Phase III Trial | BioSpace https://t.co/CjEVVpnh1y #jobs'
2021-01-01,b'RT @newsfilterio: New patent application published for: Pharmaceutical Compositions Comprising Meloxicam $AXSM https://t.co/0I47d23kal'
2021-01-01,"b'RT @BobMarshall63: $AXSM I counted 18, yes 18!, materially positive announcements in 2020 - trial results, FDA advancements and bus dev.  N\xe2\x80\xa6'"
2021-01-01,"b'RT @BobMarshall63: $AXSM I counted 18, yes 18!, materially positive announcements in 2020 - trial results, FDA advancements and bus dev.  N\xe2\x80\xa6'"
2021-01-01,b'New patent application published for: Pharmaceutical Compositions Comprising Meloxicam $AXSM https://t.co/0I47d23kal'
2021-01-01,b'New patent application published for: Pharmaceutical Compositions Comprising Meloxicam $AXSM https://t.co/tvpBDbl7YV'
2020-12-31,"b'Evening Most Tweeted Mid Caps, check out Gambiste Top 10: $OSTK $FUTU $HYLN $PRPL $AXSM $CWH $MAXR $SGMO $GRWG https://t.co/k3uyuEbRpJ'"
2020-12-31,b'$AXSM Axsome\xe2\x80\x99s Migraine Drug Provides Relief in Phase III Trial | BioSpace https://t.co/CjEVVpnh1y #jobs'
2020-12-31,"b""$axsm stellar 2019 ; sideway 2020 ; 2021?  top tier mgmt team, at 3B, w/ so much pipeline, it's inexpensive.  eventually a BO at 200-250$ min within 2 yrs imho.  if you want snail paced, steady, solid execution, AXSM is in your top 5 list.  love the CEO who has not sold a share"""
2020-12-31,b'PIPELINE (cont.):\n$AXSM (-2.15%) Results from the ph 3 long-term trial\n\nlinks to source info here =&gt; https://t.co/iraLdEDqBN\n\n(2/2)'
2020-12-31,b'Biopharma Daily Stock Updates 12/31/20\n\n$XBI $140.78 (-2.29%) \xf0\x9f\x93\x89\n\nCOVID:\n$RDHL (-5.61%) Data from ph 2 #SARSCoV2 study\n$MRNA (-5.99%) Publication of results in NEJM\n$MRNA (-5.99%) 40M #SARSCoV2 vaccine supply agreement Korea\n\nPIPELINE:\n$AXSM (-2.15%) Initiates ph 3 trial\n\n(1/2)'
2020-12-31,b'$AXSM Bearish Engulfing\nDaily appearances since 2015: 46\nClose 5 days later \xc2\xb1:\nAvg: 0.52\nSD: 8.67\nWorst: -14.07\nBest: 53.88\n\n10 days later:\nAvg: 0.43\nSD: 9.36\nWorst: -13.68\nBest: 57.04\n\n30 days later:\nAvg: -0.04\nSD: 12.14\nWorst: -48.07\nBest: 43.23'
2020-12-31,"b""@DavidNohejl You should feel great. 2021 is all about metals &amp; crypto as I've learned biotech isn't my expertise. Found a gem but $BCLI slapped me silly after 300% gains when greed kicked in but holding $AUPH $ONCT $PAVM $XAIR $AXSM $APTO $OCUL in smaller amounts. Lots of lessons learned. HNY"""
2020-12-31,b'RT @LifeSciFocus: $AXSM COWEN CONTINUES TO VIEW SHARES AS UNDERVALUED\n\nPRICE TARGET: $135 https://t.co/niqoXNM1Q6'
2020-12-31,b'RT @LifeSciFocus: $AXSM COWEN CONTINUES TO VIEW SHARES AS UNDERVALUED\n\nPRICE TARGET: $135 https://t.co/niqoXNM1Q6'
2020-12-31,b'$AXSM COWEN CONTINUES TO VIEW SHARES AS UNDERVALUED\n\nPRICE TARGET: $135 https://t.co/niqoXNM1Q6'
2020-12-31,b'@beachbumcapital @BobMarshall63 $axsm I don\xe2\x80\x99t see buyout happening immediately but I love the potential for commercialization to make this hit 200$ in a year and a half. Great entry price even here. Cro owns 8M shares and hasn\xe2\x80\x99t sold a single one despite over 100x appreciation and it being his entire wealth'
2020-12-31,"b'RT @BobMarshall63: $AXSM I counted 18, yes 18!, materially positive announcements in 2020 - trial results, FDA advancements and bus dev.  N\xe2\x80\xa6'"
2020-12-31,"b""$AXSM's in Uptrend: Moving Average Convergence Divergence (MACD) Histogram just turned positive. View odds for this and other indicators: https://t.co/GhyaVve1jB #AxsomeTherapeutics #stockmarket #stock #technicalanalysis #money #trading #investing #daytrading #news #today https://t.co/FZho2qiGbm"""
2020-12-31,"b'RT @BioStocks: $AXSM Achieved migraine pain relief in ~ 70% of patients, and pain freedom in ~ 40% of patients, at 2 hours\n\nAchieved durabl\xe2\x80\xa6'"
2020-12-31,b'@BlahowetzK I believe $AXSM investors this year are even harder to treat than TRD patients themselves.'
2020-12-31,b'RT @BioStocks: $AXSM Announces Positive Efficacy and Safety Results from the Phase 3 MOVEMENT Long-Term Trial of AXS-07 in the Acute Treatm\xe2\x80\xa6'
2020-12-31,b'In $AXSM\xe2\x80\x99s defense at least they\xe2\x80\x99re doing everything they can to increase the size of the depression market'
2020-12-31,b'RT @BioStocks: $AXSM Initiates ACCORD Phase 3 Trial of AXS-05 in Alzheimer\xe2\x80\x99s Disease Agitation.'
2020-12-31,b'Axsome Therapeutics Initiates ACCORD Phase 3 Trial of AXS-05 in Alzheimer\xe2\x80\x99s Disease Agitation! No treatments are currently approved for Alzheimer\xe2\x80\x99s disease agitation! $AXSM #biotech #CNS #neuroscience \nhttps://t.co/x89NP4RQg8 https://t.co/XKwaEEAVvV'
2020-12-31,b'$AXSM and $KPTI officially the shittiest stocks of 2020'
2020-12-31,b'Axsome Therapeutics Initiates ACCORD Phase 3 Trial of AXS-05 in Alzheimer\xe2\x80\x99s Disease Agitation! No treatments are currently approved for Alzheimer\xe2\x80\x99s disease agitation! $AXSM #biotech #CNS #neuroscience \nhttps://t.co/XIZyUwhML2 https://t.co/QDrIq8pOUZ'
2020-12-31,b'RT @BobMarshall63: FWIW changes in LT account - large positions in order: $TGTX $AXSM $DMTK $IPOC $SGMO $XAIR $BTAI $OCUL $KALA $ONCT $TCON\xe2\x80\xa6'
2020-12-31,b'$AXSM Axsome Therapeutics Initiates ACCORD Phase 3 Trial of AXS-05 in Alzheimer\xe2\x80\x99s Disease Agitation https://t.co/yL17x3Fogz'
2020-12-31,"b'RT @wfc19: $AXSM Of course, positive phase 3 data reported again and the stock in read again. \xf0\x9f\x98\x82'"
2020-12-31,"b'$AXSM Of course, positive phase 3 data reported again and the stock in read again. \xf0\x9f\x98\x82'"
2020-12-31,b'$AXSM Axsome Therapeutics Announces Positive Efficacy and Safety Results from the Phase 3 MOVEMENT Long-Term Trial of AXS-07 in the Acute Treatment of Migraine https://t.co/vORBBMvEAI'
2020-12-31,b'$axsm Axsome Therapeutics (AXSM) Begins ACCORD Phase 3 Trial of AXS-05 in Alzheimer\xe2\x80\x99s Disease Agitation'
2020-12-31,b'RT @BioStocks: $AXSM Announces Positive Efficacy and Safety Results from the Phase 3 MOVEMENT Long-Term Trial of AXS-07 in the Acute Treatm\xe2\x80\xa6'
2020-12-31,"b'Recent $AXSM technical alerts: Non-ADX 1,2,3,4 Bullish plus 3 more alerts... https://t.co/GD05wWU2WA'"
2020-12-31,b'Headline Watchlist 12-31-20: HAPPY NEW YEAR TRADERS $HOTH $CAN $PED $HUSN $EBON $NNDM $OEG $SINO\n$OPK $SFET $TGA $LXRX $AXSM $DDD $UONE $MGEN #daytrading https://t.co/zGGxsP0Sbc'
2020-12-31,b'$AXSM \nReiterated by UBS Positive\nhttps://t.co/GlOdaISpvm'
2020-12-31,b'RT @BioStocks: $AXSM Announces Positive Efficacy and Safety Results from the Phase 3 MOVEMENT Long-Term Trial of AXS-07 in the Acute Treatm\xe2\x80\xa6'
2020-12-31,b'RT @BioStocks: $AXSM Announces Positive Efficacy and Safety Results from the Phase 3 MOVEMENT Long-Term Trial of AXS-07 in the Acute Treatm\xe2\x80\xa6'
2020-12-31,b'$AXSM double PR. Alz initiation and positive phase 3 migraine. Seriously undervalued at 3b market cap'
2020-12-31,"b'$AXSM I counted 18, yes 18!, materially positive announcements in 2020 - trial results, FDA advancements and bus dev.  Not counting pos announcements on cash position, general advancement. NO insiders have sold. 2021?  Better r/r now than mid 2019 when it then went 4x.'"
2020-12-31,b'RT @BioStocks: $AXSM Initiates ACCORD Phase 3 Trial of AXS-05 in Alzheimer\xe2\x80\x99s Disease Agitation.'
2020-12-31,b'RT @BioStocks: $AXSM Announces Positive Efficacy and Safety Results from the Phase 3 MOVEMENT Long-Term Trial of AXS-07 in the Acute Treatm\xe2\x80\xa6'
2020-12-31,"b'RT @BioStocks: $AXSM Achieved migraine pain relief in ~ 70% of patients, and pain freedom in ~ 40% of patients, at 2 hours\n\nAchieved durabl\xe2\x80\xa6'"
2020-12-31,b'RT @BioStocks: $AXSM Announces Positive Efficacy and Safety Results from the Phase 3 MOVEMENT Long-Term Trial of AXS-07 in the Acute Treatm\xe2\x80\xa6'
2020-12-31,b'RT @BioStocks: $AXSM Initiates ACCORD Phase 3 Trial of AXS-05 in Alzheimer\xe2\x80\x99s Disease Agitation.'
2020-12-31,b'$AXSM: Axsome Therapeutics reports efficacy and safety results from the Phase 3 MOVEMENT long-term trial of AXS-07;... https://t.co/GIDeZegruS'
2020-12-31,b'$AXSM initiates ACCORD Phase 3 trial of AXS-05 in Alzheimer\xe2\x80\x99s Disease Agitation'
2020-12-31,b'$AXSM reports efficacy and safety results from the Phase 3 MOVEMENT long-term trial of AXS-07; NDA on track for submission in 1Q 202'
2020-12-31,b'RT @InvestrClouseau: $AXSM really needs to fire whichever IR consultant told them it was OK to release data today. And also released depres\xe2\x80\xa6'
2020-12-31,b'RT @BioStocks: $AXSM Initiates ACCORD Phase 3 Trial of AXS-05 in Alzheimer\xe2\x80\x99s Disease Agitation.'
2020-12-31,b'RT @BioStocks: $AXSM Announces Positive Efficacy and Safety Results from the Phase 3 MOVEMENT Long-Term Trial of AXS-07 in the Acute Treatm\xe2\x80\xa6'
2020-12-31,b'$AXSM initiates placebo controlled AZ agitation trial with open label extension for safety/efficacy. Will establish long term benefit as CONCERT did w MDD. AXS-05 potential revenue monster imo\nhttps://t.co/jradMho2B5'
2020-12-31,b'Was thinking this myself when I saw news. Terrible timing. $AXSM https://t.co/oiPrix03Kn https://t.co/letZO1FiWC'
2020-12-31,b'@semodough Nothing but series of good news all thru 2019-20.  Not sure why investors still kicking the can when pipeline &amp; data is as strong as ever.  $AXSM Long.  We will wake up one day on a high premium buyout news.'
2020-12-31,b'$AXSM really needs to fire whichever IR consultant told them it was OK to release data today. And also released depression data over two days inexplicably IIRC'
2020-12-31,b'RT @BioStocks: $AXSM Announces Positive Efficacy and Safety Results from the Phase 3 MOVEMENT Long-Term Trial of AXS-07 in the Acute Treatm\xe2\x80\xa6'
2020-12-31,"b'RT @_B_I_O_T_E_C_H_: $AXSM AXSOME THERAPEUTICS INC - STUDY ACHIEVED DURABLE RELIEF, WITH APPROXIMATELY 85% OF PATIENTS FREE FROM RESCUE MED\xe2\x80\xa6'"
2020-12-31,"b'$AXSM Axsome Therapeutics, Inc. SEC Filing: Form 8-K https://t.co/Yzj9AzgeM3'"
2020-12-31,"b'Disclosure Alert: $AXSM says Phase 3 migraine treatment a success, relieved pain in 70% of patients, on track to file NDA submission Q1 2021'"
2020-12-31,"b""Also, if you are new to $AXSM here's a background article on Finpedia for you https://t.co/7ObjQl5pDQ"""
2020-12-31,"b'$AXSM / Axsome Therapeutics files form 8-K - Financial Statements and Exhibits, Other Events -  8-K https://t.co/YIQ1Qxphzz'"
2020-12-31,"b'A Form 8-K [Press/News Current Report] filing has been made with the SEC:  $AXSM #AxsomeTherapeutics, Inc  https://t.co/licWSDlRK1'"
2020-12-31,"b'RT @_B_I_O_T_E_C_H_: $AXSM AXSOME THERAPEUTICS INC - STUDY ACHIEVED DURABLE RELIEF, WITH APPROXIMATELY 85% OF PATIENTS FREE FROM RESCUE MED\xe2\x80\xa6'"
2020-12-31,b'RT @BioStocks: $AXSM Announces Positive Efficacy and Safety Results from the Phase 3 MOVEMENT Long-Term Trial of AXS-07 in the Acute Treatm\xe2\x80\xa6'
2020-12-31,"b'RT @_B_I_O_T_E_C_H_: $AXSM AXSOME THERAPEUTICS INC - STUDY ACHIEVED DURABLE RELIEF, WITH APPROXIMATELY 85% OF PATIENTS FREE FROM RESCUE MED\xe2\x80\xa6'"
2020-12-31,"b'RT @_B_I_O_T_E_C_H_: $AXSM AXSOME THERAPEUTICS INC - STUDY ACHIEVED DURABLE RELIEF, WITH APPROXIMATELY 85% OF PATIENTS FREE FROM RESCUE MED\xe2\x80\xa6'"
2020-12-31,b'RT @BioStocks: $AXSM Announces Positive Efficacy and Safety Results from the Phase 3 MOVEMENT Long-Term Trial of AXS-07 in the Acute Treatm\xe2\x80\xa6'
2020-12-31,b'RT @BioStocks: $AXSM Initiates ACCORD Phase 3 Trial of AXS-05 in Alzheimer\xe2\x80\x99s Disease Agitation.'
2020-12-31,"b'RT @kevinjaybe: $AXSM *Achieved migraine pain relief in approximately 70% of patients, and pain freedom in approximately 40% of patients, a\xe2\x80\xa6'"
2020-12-31,"b""RT @ATLanalyst: Reading $AXSM's ok migraine data just makes me shake my head recalling $ZSAN's fabulous migraine data, but management getti\xe2\x80\xa6"""
2020-12-31,b'RT @otcdynamics: $AXSM Axsome Therapeutics Initiates ACCORD Phase 3 Trial of AXS-05 in Alzheimer\xe2\x80\x99s Disease Agitation https://t.co/h8T1qLDJlv'
2020-12-31,b'RT @CHItraders: $AXSM Axsome therapeutics initiates ACCORD phase 3 trial of AXS-05 in alzheimer\xe2\x80\x99s disease agitation https://t.co/OoWdKbF24H'
2020-12-31,b'$AXSM Axsome therapeutics initiates ACCORD phase 3 trial of AXS-05 in alzheimer\xe2\x80\x99s disease agitation https://t.co/OoWdKbF24H'
2020-12-31,"b'RT @BioStocks: $AXSM Achieved migraine pain relief in ~ 70% of patients, and pain freedom in ~ 40% of patients, at 2 hours\n\nAchieved durabl\xe2\x80\xa6'"
2020-12-31,b'RT @BioStocks: $AXSM Announces Positive Efficacy and Safety Results from the Phase 3 MOVEMENT Long-Term Trial of AXS-07 in the Acute Treatm\xe2\x80\xa6'
2020-12-31,b'$AXSM Reveals Findings from Late-Stage Long-Term Trial of AXS-07 in the Acute Treatment of Migraine       #AxsomeTherapeutics    https://t.co/dww1iExdvg'
2020-12-31,b'RT @BioStocks: $AXSM Initiates ACCORD Phase 3 Trial of AXS-05 in Alzheimer\xe2\x80\x99s Disease Agitation.'
2020-12-31,"b""RT @ATLanalyst: Reading $AXSM's ok migraine data just makes me shake my head recalling $ZSAN's fabulous migraine data, but management getti\xe2\x80\xa6"""
2020-12-31,b'$AXSM Axsome Therapeutics Initiates ACCORD Phase 3 Trial of AXS-05 in Alzheimer\xe2\x80\x99s Disease Agitation https://t.co/h8T1qLDJlv'
2020-12-31,"b'RT @_B_I_O_T_E_C_H_: $AXSM AXSOME THERAPEUTICS INC - STUDY ACHIEVED DURABLE RELIEF, WITH APPROXIMATELY 85% OF PATIENTS FREE FROM RESCUE MED\xe2\x80\xa6'"
2020-12-31,b'RT @kevinjaybe: $AXSM Announces Positive Efficacy and Safety Results from the Phase 3 MOVEMENT Long-Term Trial of AXS-07 in the Acute Treat\xe2\x80\xa6'
2020-12-31,"b'RT @kevinjaybe: $AXSM *Achieved migraine pain relief in approximately 70% of patients, and pain freedom in approximately 40% of patients, a\xe2\x80\xa6'"
2020-12-31,b'RT @BioStocks: $AXSM Initiates ACCORD Phase 3 Trial of AXS-05 in Alzheimer\xe2\x80\x99s Disease Agitation.'
2020-12-31,b'$AXSM - Axsome therapeutics initiates ACCORD phase 3 trial of AXS-05 in alzheimer\xe2\x80\x99s disease agitation https://t.co/AITGMbOwyG'
2020-12-31,b'RT @semodough: $AXSM  Positive Efficacy and Safety Results from  Phase 3 MOVEMENT Long-Term Trial of AXS-07 in the Acute Treatment of Migra\xe2\x80\xa6'
2020-12-31,"b""Reading $AXSM's ok migraine data just makes me shake my head recalling $ZSAN's fabulous migraine data, but management getting a discipline review letter and CRL from the FDA and thus sits at $.55 shareprice."""
2020-12-31,"b'$AXSM *Achieved migraine pain relief in approximately 70% of patients, and pain freedom in approximately 40% of patients, at 2 hours\n\n*Achieved durable relief, with approximately 85% of patients free from rescue medication use over 48 hours\n\n*NDA on track for submission in 1Q21'"
2020-12-31,b'RT @BioStocks: $AXSM Announces Positive Efficacy and Safety Results from the Phase 3 MOVEMENT Long-Term Trial of AXS-07 in the Acute Treatm\xe2\x80\xa6'
2020-12-31,b'$AXSM Announces Positive Efficacy and Safety Results from the Phase 3 MOVEMENT Long-Term Trial of AXS-07 in the Acute Treatment of Migraine https://t.co/WecRmLAxNs'
2020-12-31,b'$AXSM Initiates ACCORD Phase 3 Trial of AXS-05 in Alzheimer\xe2\x80\x99s Disease Agitation https://t.co/0bSXwObCVI'
2020-12-31,b'RT @semodough: $AXSM  Positive Efficacy and Safety Results from  Phase 3 MOVEMENT Long-Term Trial of AXS-07 in the Acute Treatment of Migra\xe2\x80\xa6'
2020-12-31,b'RT @BioStocks: $AXSM Initiates ACCORD Phase 3 Trial of AXS-05 in Alzheimer\xe2\x80\x99s Disease Agitation.'
2020-12-31,"b""Hey y'all I have a real #feelgood play today \xf0\x9f\x92\x83\xf0\x9f\xa7\xac\xf0\x9f\x94\xac $axsm I don't know much about this company but they have #six drugs out now treating different types of #pain from #kneearthritis\xf0\x9f\xa7\x8e to #lowerbackpain \xf0\x9f\x91\xa8\xe2\x80\x8d\xf0\x9f\x92\xbbto #depression \xf0\x9f\x98\xadand now  #migraines \xf0\x9f\xa4\x95 https://t.co/7fCowYtTdx"""
2020-12-31,"b'$AXSM  Positive Efficacy and Safety Results from  Phase 3 MOVEMENT Long-Term Trial of AXS-07 in the Acute Treatment of Migraine Achieved migraine pain relief in approximately 70% of patients, and pain freedom in approximately 40% of patients, at 2 hours\n https://t.co/hUeTWtkXSa'"
2020-12-31,b'$AXSM Axsome Therapeutics Initiates ACCORD Phase 3 Trial of AXS-05 in Alzheimer\xe2\x80\x99s Disease Agitation Nasdaq:AXSM https://t.co/fFI7pcN8Ts'
2020-12-31,"b'RT @BioStocks: $AXSM Achieved migraine pain relief in ~ 70% of patients, and pain freedom in ~ 40% of patients, at 2 hours\n\nAchieved durabl\xe2\x80\xa6'"
2020-12-31,b'RT @BioStocks: $AXSM Announces Positive Efficacy and Safety Results from the Phase 3 MOVEMENT Long-Term Trial of AXS-07 in the Acute Treatm\xe2\x80\xa6'
2020-12-31,b'RT @BioStocks: $AXSM Announces Positive Efficacy and Safety Results from the Phase 3 MOVEMENT Long-Term Trial of AXS-07 in the Acute Treatm\xe2\x80\xa6'
2020-12-31,b'$AXSM Initiates ACCORD Phase 3 Trial of AXS-05 in Alzheimer\xe2\x80\x99s Disease Agitation.'
2020-12-31,b'Axsome Therapeutics initiates ACCORD Phase 3 trial of AXS-05\n$AXSM'
2020-12-31,b'RT @BobMarshall63: FWIW changes in LT account - large positions in order: $TGTX $AXSM $DMTK $IPOC $SGMO $XAIR $BTAI $OCUL $KALA $ONCT $TCON\xe2\x80\xa6'
2020-12-31,b'$AXSM Axsome Therapeutics Initiates ACCORD Phase 3 Trial of AXS-05 in Alzheimer\xe2\x80\x99s Disease Agitation\nhttps://t.co/Wd7DiU1X2q'
2020-12-31,b'$AXSM Axsome Therapeutics Announces Positive Efficacy and Safety Results from the Phase 3 MOVEMENT Long-Term Trial of AXS-07 in the Acute Treatment of Migraine https://t.co/iLXJqdczPV'
2020-12-31,b'RT @BioStocks: $AXSM Announces Positive Efficacy and Safety Results from the Phase 3 MOVEMENT Long-Term Trial of AXS-07 in the Acute Treatm\xe2\x80\xa6'
2020-12-31,b'RT @BioStocks: $AXSM Announces Positive Efficacy and Safety Results from the Phase 3 MOVEMENT Long-Term Trial of AXS-07 in the Acute Treatm\xe2\x80\xa6'
2020-12-31,"b'RT @BioStocks: $AXSM Achieved migraine pain relief in ~ 70% of patients, and pain freedom in ~ 40% of patients, at 2 hours\n\nAchieved durabl\xe2\x80\xa6'"
2020-12-31,b'Axsome Therapeutics announces results from Phase 3 MOVEMENT trial of AXS-07\n$AXSM'
2020-12-31,"b'$AXSM Achieved migraine pain relief in ~ 70% of patients, and pain freedom in ~ 40% of patients, at 2 hours\n\nAchieved durable relief, with ~ 85% of patients free from rescue medication use over 48 hours'"
2020-12-31,"b""$AXSM Announces Positive Efficacy and Safety Results from the Phase 3 MOVEMENT Long-Term Trial of AXS-07 in the Acute Treatment of Migraine.\n\nNDA on track for submission in Q1'21"""
2020-12-31,"b'$AXSM AXSOME THERAPEUTICS INC - STUDY ACHIEVED DURABLE RELIEF, WITH APPROXIMATELY 85% OF PATIENTS FREE FROM RESCUE MEDICATION USE OVER 48 HOURS ACHIEVED MIGRAINE PAIN RELIEF IN APPROXIMATELY 70% OF PATIENTS, AND PAIN FREEDOM IN APPROXIMATELY 40% OF PATIENTS, AT 2 HOURS'"
2020-12-31,b'$AXSM Axsome Therapeutics Announces Positive Efficacy and Safety Results from the Phase 3 MOVEMENT Long-Term Trial of AXS-07 in the Acute Treatment of Migraine\nhttps://t.co/HbIZlBov3R'
2020-12-31,b'Video (Investing &amp; Trading: Your Most Important Investment For New Year 2021!)https://t.co/fbF82PkjQB?\n#DrTranBioSci #IntegratedBioSciInvesting #biotech #trading #investing #retirement #tradingsecrets $AXSM $IOVA $CYRX $CRSP $ITCI $AXSM $CORI $JUNO $KITE $ONCE $TSRO'
2020-12-31,b'Real Retirement Secrets: Your Most Important Investments! https://t.co/NrVtyqao8U\n#DrTranBioSci #IntegratedBioSciInvesting #biotech #trading #investing #retirement #tradingsecrets $AXSM $IOVA $CYRX $CRSP $ITCI $AXSM $CORI $JUNO $KITE $ONCE $TSRO https://t.co/mFdjqMAmCD'
2020-12-30,b'$AXSM Below Avg Volume\nDaily appearances since 2015: 690\nClose 5 days later \xc2\xb1:\nAvg: -0.04\nSD: 1.18\nWorst: -7.87\nBest: 8.62\n\n10 days later:\nAvg: -0.01\nSD: 1.61\nWorst: -7.76\nBest: 11.77\n\n30 days later:\nAvg: -0.01\nSD: 2.19\nWorst: -9.01\nBest: 14.06'
2020-12-30,"b'RT @MrMiyagann: #COVID19: According to #JAMA 3x more #Americans are now #depressed. Next up, everyone is forced on #vaccine, uppers and #di\xe2\x80\xa6'"
2020-12-30,"b'#COVID19: According to #JAMA 3x more #Americans are now #depressed. Next up, everyone is forced on #vaccine, uppers and #diabetes meds. Yay for #science based #lockdowns.. fucking clowns..\n\n#Canada #Ontario @fordnation $TNDM $PODD $DXCM $MDT $AXSM https://t.co/d34lkM5Rnd'"
2020-12-30,b'@Pharmdca The one and only $AXSM. Ugh'
2020-12-30,b'Stocks to watch Dec. 30 thru Dec. 31 $Lthm $sdgr $fit $ccj $bLdp $rs $scu $pbi $axsm $acy $uuu $tenx $uavs $tnxp $nova &amp; $BIOL BIOLASE INC. https://t.co/mh9yMraMLE stock tip $BIOL'
2020-12-29,"b'@sentivcapital @semodough Yep. $TCON is unique in the sense utilizes cost-efficient, CRO-independent product development platform to partner with ex-US companies to develop and commercialize drugs in US.  Reminds me of $AXSM when it was in teens. Both CEO\xe2\x80\x99s world class.'"
2020-12-29,b'RT @Biotech2k1: Picked up a little $ADAP for my IRA. I now have 5 names in there I think are very under appreciated in this market for next\xe2\x80\xa6'
2020-12-29,"b'Picked up a little $ADAP for my IRA. I now have 5 names in there I think are very under appreciated in this market for next year. They include $DCPH, $AXSM, $KRTX and $MYOV. Looking for value in a very bubbly market.'"
2020-12-29,b'@kinneklaus @scottmelker And imo target drugs unconstrained by recession and/or will increase in demand bc of pand.  $AXSM example LT play bc depression exploding (demand +) Alz agitation (unaffected by resc plus demographic growth)'
2020-12-28,b'Domo arigato Mr. Roboto is what you will be saying after you sell your human children and buy Axsome Therapeutics $AXSM #StonksOnlyGoUp'
2020-12-28,b'$AXSM Below Avg Volume\nDaily appearances since 2015: 690\nClose 5 days later \xc2\xb1:\nAvg: -0.04\nSD: 1.18\nWorst: -7.87\nBest: 8.62\n\n10 days later:\nAvg: -0.02\nSD: 1.61\nWorst: -7.76\nBest: 11.77\n\n30 days later:\nAvg: -0.02\nSD: 2.16\nWorst: -9.01\nBest: 14.06'
2020-12-28,"b'RT @ToneVays: 2/2: #Shitcoin(ers) think they found something knew, but they blew it on real gains. Hindsight analysis shows the best invest\xe2\x80\xa6'"
2020-12-28,b'RT @WayoftheMaster7: $QS $ADBE $MAS $TTCF $KNTE $BEAM $EH $CMBM $HELE $CLSK $QLD $AXSM $IPOD $HRTX $YEXT $LOVE $CCCC..... #TheStrat https:/\xe2\x80\xa6'
2020-12-28,"b""RT @WayoftheMaster7: Hit em if you want em! #TheStrat \n\nInside D Add's... $SWTX $ALGM $CLSK $NGA $KOD $BILI $SEDG $SPWR $TME $BILL\n\n3-1 D..\xe2\x80\xa6"""
2020-12-28,b'$DMTK $TCRR $OVID $MRNA $SILK $TBIO $MYOV $AXSM $HALO $TFFP $VAPO $RCKT $TWST $TGTX $CRDF $EVLO  There More Room To Run For These Biotech Stock Picks That Delivered Triple Digit Gains?https://t.co/Ovf6SHVoAL'
2020-12-28,b'RT @FalconStocks: .\nTODAY - Another Double - VTGN\n\nhttps://t.co/JX4QNct8lt\n100% Unbiased\n16 Years Online\n\n$BTC $AAPL $TRX $BCH $EOS $QEDN $\xe2\x80\xa6'
2020-12-28,b'https://t.co/uXrnzGx5C2 Axsome Therapeutics Inc The network is predicting this company s stock price should remain flat in the coming days and has a neutral long term price outlook $AXSM #finance #stockmarket #goals'
2020-12-28,b'RT @stb8444: @IlliniJJ I wish $tptx $mrtx and $axsm would have a baby and I could invest in it.'
2020-12-28,b'RT @stb8444: @IlliniJJ I wish $tptx $mrtx and $axsm would have a baby and I could invest in it.'
2020-12-28,b'@IlliniJJ I wish $tptx $mrtx and $axsm would have a baby and I could invest in it.'
2020-12-28,"b'RT @JD4for4: My top names for 2021 \xe2\x80\x94 $XAIR - FDA approval PPHN &amp; NTM data (5x upside), $TRIL ASH data + solid tumors (3x), $IPOC AI health\xe2\x80\xa6'"
2020-12-28,b'@semodough $DRNA 600 million cash. $AXSM 200 million cash.'
2020-12-28,b'https://t.co/uXrnzGx5C2 Axsome Therapeutics Inc The artificial intelligence assessed this company s stock price is aligned with its true value for now and is neither a long or short opportunity in the longer term $AXSM #money #invest #trader'
2020-12-27,b'$AXSM should see multiple PRs this week with initiation of alz agitation trial and AXS-07 migraine data. Maybe we get back to triple digits'
2020-12-27,b'RT @semodough: $AXSM AXS-05 - January 2021 - NDA submission in MDD AXS-07 - 1Q21 - NDA submission in migraine'
2020-12-27,"b'RT @JD4for4: My top names for 2021 \xe2\x80\x94 $XAIR - FDA approval PPHN &amp; NTM data (5x upside), $TRIL ASH data + solid tumors (3x), $IPOC AI health\xe2\x80\xa6'"
2020-12-27,"b'RT @JD4for4: My top names for 2021 \xe2\x80\x94 $XAIR - FDA approval PPHN &amp; NTM data (5x upside), $TRIL ASH data + solid tumors (3x), $IPOC AI health\xe2\x80\xa6'"
2020-12-27,b'Real Trading/Investing/Retirement Secrets: How You Can Capture A Rallying Stocks Like Alpine?\nhttps://t.co/HqLqXzkhEh\n#DrTranBioSci #IntegratedBioSciInvesting #biotech #trading #investing #stockmarket #tradingsecrets #investingsecrets $ALPN $CRSP $CYRX $MRT $AXSM $ITCI $XBI $DJIA'
2020-12-27,b'RT @semodough: $AXSM AXS-05 - January 2021 - NDA submission in MDD AXS-07 - 1Q21 - NDA submission in migraine'
2020-12-27,b'RT @semodough: $AXSM AXS-05 - January 2021 - NDA submission in MDD AXS-07 - 1Q21 - NDA submission in migraine'
2020-12-27,b'$AXSM AXS-05 - January 2021 - NDA submission in MDD AXS-07 - 1Q21 - NDA submission in migraine'
2020-12-26,"b'RT @JD4for4: My top names for 2021 \xe2\x80\x94 $XAIR - FDA approval PPHN &amp; NTM data (5x upside), $TRIL ASH data + solid tumors (3x), $IPOC AI health\xe2\x80\xa6'"
2021-01-07,b'@jfais20 $BTAI and $AXSM in Alzheimers agitation (but $BTAI in acute vs. $AXSM in chronic)'
2021-01-07,b'$AXSM Needs to rebound at some point  -3.81 % change recently\n https://t.co/KMYVaiWLJo'
2021-01-07,"b'RT @TomSilver39: Mizuho 2021 SMID Biotech Outlook: Top picks in 2021 which are $SRPT, $CNCE, $BLUE, and $FGEN. Biopharma Outlook; Top Picks\xe2\x80\xa6'"
2021-01-07,"b'$AXSM Biopharmas Acute Migraine Trial Yields Positive Efficacy, Safety Results https://t.co/A266bXWGxF via @SWReports #Investing'"
2021-01-07,"b'RT @TomSilver39: Mizuho 2021 SMID Biotech Outlook: Top picks in 2021 which are $SRPT, $CNCE, $BLUE, and $FGEN. Biopharma Outlook; Top Picks\xe2\x80\xa6'"
2021-01-07,"b'RT @TomSilver39: Mizuho 2021 SMID Biotech Outlook: Top picks in 2021 which are $SRPT, $CNCE, $BLUE, and $FGEN. Biopharma Outlook; Top Picks\xe2\x80\xa6'"
2021-01-07,"b'RT @TomSilver39: Mizuho 2021 SMID Biotech Outlook: Top picks in 2021 which are $SRPT, $CNCE, $BLUE, and $FGEN. Biopharma Outlook; Top Picks\xe2\x80\xa6'"
2021-01-07,"b'Mizuho 2021 SMID Biotech Outlook: Top picks in 2021 which are $SRPT, $CNCE, $BLUE, and $FGEN. Biopharma Outlook; Top Picks are : $ABBV, $ACAD, $ALKS, $KRTX and $AXSM .""'"
2021-01-07,"b""$AXSM's in Downtrend: Moving Average Convergence Divergence (MACD) Histogram just turned negative. View odds for this and other indicators: https://t.co/zymAYG4a9n #AxsomeTherapeutics #stockmarket #stock #technicalanalysis #money #trading #investing #daytrading #news #today https://t.co/OCUI8AJdyq"""
2021-01-07,b'$AXSM - Implied Volatility Surging for Axsome Therapeutics (AXSM) Stock Options https://t.co/ujfD4gpUUk https://t.co/joUrQJ6x0M'
2021-01-07,"b'RT @semodough: Mizuho 2021 Biopharma Outlook; Top Picks are $ABBV, $ACAD, $ALKS, $KRTX $AXSM'"
2021-01-07,"b'RT @semodough: Mizuho 2021 Biopharma Outlook; Top Picks are $ABBV, $ACAD, $ALKS, $KRTX $AXSM'"
2021-01-07,"b'RT @semodough: Mizuho 2021 Biopharma Outlook; Top Picks are $ABBV, $ACAD, $ALKS, $KRTX $AXSM'"
2021-01-07,b'$AXSM Wake me up when we are green .. lol.  \xef\xbf\xbd\xef\xbf\xbd\xef\xbf\xbd\xef\xbf\xbd\xef\xbf\xbd\xef\xbf\xbd -3.81 % change recently https://t.co/KMYVaiFakO'
2021-01-07,"b'RT @semodough: Mizuho 2021 Biopharma Outlook; Top Picks are $ABBV, $ACAD, $ALKS, $KRTX $AXSM'"
2021-01-07,"b'Mizuho 2021 Biopharma Outlook; Top Picks are $ABBV, $ACAD, $ALKS, $KRTX $AXSM'"
2021-01-07,b'$AXSM damn if we pass $68.00  -3.84 % change recently https://t.co/KMYVaiFakO'
2021-01-06,"b""Biopharma's Acute Migraine Trial Yields Positive Efficacy, Safety Results: https://t.co/eknvo3gl1I\n\nTopline results from Axsome Therapeutics' MOVEMENT study are reviewed in a Ladenburg Thalmann report.\n\n$AXSM #migraine #stocks Axsome Therapeutics, Inc. @AxsomeTx https://t.co/ORSChG3CPN"""
2021-01-06,b'Scan results - Fell Below 50 DMA today: $ARE $RPM $PCTY $CL $AVLR $FCFS $PFSI $ATSG $EPAM $NVDA $AXSM $ADBE $GOOG $TCP $VRSN $CPB $GOOGL $INCY $NOW $AKAM ... https://t.co/Ooyp8Kr8d3'
2021-01-06,b'$AXSM Minor Breakdown\nDaily appearances since 2015: 49\nClose 5 days later \xc2\xb1:\nAvg: 0.90\nSD: 5.05\nWorst: -18.31\nBest: 20.97\n\n10 days later:\nAvg: 0.48\nSD: 5.14\nWorst: -16.88\nBest: 14.64\n\n30 days later:\nAvg: 1.90\nSD: 10.51\nWorst: -25.62\nBest: 53.41'
2021-01-06,"b""Biopharma's Acute Migraine Trial Yields Positive Efficacy, Safety Results: https://t.co/sS3f9K0Gxj\n\nTopline results from Axsome Therapeutics' MOVEMENT study are reviewed in a Ladenburg Thalmann report.\n\n$AXSM #migraine #stocks @AxsomeTx https://t.co/0u8W5BO4XV"""
2021-01-06,"b'RT @DeepSouthDoctor: Re-bought $AXSM at $76. Ought to have approval for Depression and Migraine indications in 2H21, several pivotal trials\xe2\x80\xa6'"
2021-01-06,"b""Bought back $axsm $pavm and $onct today. Technically never sold out $axsm. It's been a sleeper in my IRA for a long long time.  This is really a wtf day for all three."""
2021-01-06,b'$AXSM auction is now open. -3.51 % change recently https://t.co/KMYVaiFakO'
2021-01-06,"b'Someone explain to me why you should not be adding to $AXSM at these levels after positive releases at the end of 2020, upcoming catalysts, and pipeline depth? @pawcio2009 @BillMiller32 @Pharmdca'"
2021-01-06,b'Added more $AXSM at $75.80. $XBI'
2021-01-06,"b'RT @DeepSouthDoctor: Re-bought $AXSM at $76. Ought to have approval for Depression and Migraine indications in 2H21, several pivotal trials\xe2\x80\xa6'"
2021-01-06,"b'Re-bought $AXSM at $76. Ought to have approval for Depression and Migraine indications in 2H21, several pivotal trials in progress. Happy to re-enter on recent weakness.'"
2021-01-06,"b'@pawcio2009 They raised twice at $1.6. You helped them to raise at $2.24; 40% higher. They were probably pleasantly surprised for the spike for no reason, would be stupid not to take advantage. They could be set with this much cash unless they do another one at $3.5. $AXSM used to do this.'"
2021-01-06,"b""$AXSM's in Downtrend: Moving Average Convergence Divergence (MACD) Histogram crosses below signal line. View odds for this and other indicators: https://t.co/gHYDWo0DA3 #AxsomeTherapeutics #stockmarket #stock #technicalanalysis #money #trading #investing #daytrading #news #today https://t.co/lXIPr5TKOc"""
